Genome-wide association studies (GWAS) have identified 2q35 and 16q12 as breast cancer (BC) susceptibility loci. However, the association between the two polymorphisms and BC remains controversial and inconsistent. We therefore performed a more precise estimation of these relationships by meta-analysing the currently available evidence from the literature. The PubMed, Ovid, Medline and Web of Science databases were searched. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strengths of the associations. Thirty studies, including 106,312 cases and 140,939 controls, were identified. Overall, significantly elevated breast cancer risk was associated with the A allele of 2q35 rs13387042 when all studies were pooled into the meta-analysis (OR 1.11, 95%CI 1.07-1.15). Additionally, the T allele of 16q12 rs3803662 was associated with significantly increased breast cancer risk (OR 1.20,. When stratifying for ethnicity, significantly increased risks were found among Caucasians, Asians and mixed ethnicities for both rs13387042 and rs3803662. For rs13387042, an association was observed for both estrogen receptor-positive (ER+) (OR 1.14, 95%CI 1.11-1.17) and ER-negative (ER-) disease (OR 1.05, 95%CI 1.01-1.09) and for progesterone receptor-positive (PR+) (OR 1.16, 95%CI 1.12-1.19) and PR-negative (PR-) disease (OR 1.07, 95%CI 1.03-1.12). Similarly, a stronger association was observed for rs3803662 with ER+ tumors (OR 1.23, 95%CI 1.13-1.32) compared with ER-tumors (OR 1.08,, and the same condition occurred for the polymorphism with PR+ tumors (OR 1.26, 95%CI 1.02-1.55) versus with PR-tumors (OR 1.15,. When stratified by BRCA mutation status, a stronger association was observed with BRCA2 carriers (OR 1.23, 95%CI 1.05-1.44) than BRCA1 carriers (OR 1.09, 95%CI 1.04-1.15). In conclusion, this meta-analysis demonstrated that the A allele of 2q35 rs13387042 and the T allele of 16q12 rs3803662 are risk factors associated with increased breast cancer susceptibility.
Breast cancer is one of the most common cancers and the primary cause of deaths of women in the world [1] . It is estimated that approximately 1.15 million new cases occur every year [2] . Researchers have reached a consensus that the environment and genetic factors may affect the susceptibility to cancer; however, the mechanism is still not understood. Breast cancer is nearly twice as common in first-degree relatives of women with the disease as in relatives of women without this history, suggesting an important role of inherited susceptibility [3] . Common variants of genes involving breast carcinogenesis-related pathways are candidate loci for cancer susceptibility [4] . Breast cancer may also be attributable to mutations in high-penetrant genes such as BRCA1 and BRCA2. However, these alleles are associated with only a small fraction of breast cancer [5] . In recent years, several genome-wide association studies have been conducted and have identified some genetic susceptibility loci that are associated with breast cancer risk. Stacey et al. [6] identified that rs13387042 at chromosome 2q35 and rs3803662 at chromosome 16q12 were associated with breast cancer. In another study, Easton et al. [7] also found rs3803662 as a risk factor for breast cancer. Although the common variants on chromosomes 2q35 and 16q12 that confer susceptibility to breast cancer have been independently replicated by subsequent studies, the results were generally inconsistent and inconclusive. Hence, we performed this meta-analysis of the published studies to clarify the inconsistencies and derive a more precise estimation of the association between the two polymorphisms and breast cancer.
Materials and methods
Search strategy. The literature included in our analysis was selected from the PubMed, Ovid, Medline, and Web of Science databases using the terms "2q35" or "rs13387042", "16q12" or "rs3803662", "polymorphism" or "variation" and "breast cancer". All potentially eligible studies published before the end of April 2013 were retrieved, and their reference lists were hand searched to find other relevant publications. Of the studies with overlapping data that were published by the same investigators, only the most recent study was included; for republished studies, only the one with the largest sample numbers was selected. All studies included in this meta-analysis were published in English and included the full text.
Studies were included if they met the following criteria: (1) evaluation of the 2q35 rs13387042 and 16q12 rs3803662 polymorphisms and breast cancer risk, (2) independent casecontrol studies or cohort studies, (3) sufficient available data to estimate an odds ratio (OR) with its 95% confidence interval (95%CI), and (4) in line with the Hardy-Weinberg equilibrium (HWE) in controls of the same ethnicity (P<0.01 was eligible); a deviation from the HWE was allowed in a mixed population. The major exclusion criteria were as follows: (1) no control population, and (2) no available genotype frequency.
Data extraction and quality assessment. Two investigators independently reviewed and extracted information from all eligible publications. Disagreement was resolved by discussion when there was a conflict. For each study, the following data were extracted: first author's surname, year of publication, country, ethnicity, source of control, Hardy-Weinberg equilibrium (HWE) status, estrogen receptor (ER) status, progesterone receptor (PR) status, total number of cases and controls, and inclusion of genotype frequency in cases and controls (Table S1 ). Studies with different ethnic groups were considered individual studies in this analysis.
Data analysis. Odds ratios with 95%CIs were used to assess the strength of the association between the 2q35 rs13387042, 16q12 rs3803662 polymorphism and breast cancer risk. The meta-analysis examined the associations between the following: (1) the allele contrast model, (2) the homozygote codominant model, (3) the heterozygote codominant model, (4) the dominant model, and (5) the recessive model. In addition, subgroup analyses were conducted based on ethnicity, ER status, and PR status. Chi-square-based Q-tests were performed to check the heterogeneity among different studies [8] . When heterogeneity existed (P<0.10), the random-effects model (the DerSimonian and Laird method) was used to estimate the summarised OR [9] ; otherwise, we conducted the fixed-effects model (Mantel and Haenszel method) [10] . Sensitivity analyses were conducted to assess the stability of the results, which means that a single study in the meta-analysis was deleted each time to reflect the influence of the individual dataset on the overall OR. Publication bias was assessed by Egger's test [11] and Begg's funnel plot [12] . P values less than 0.05 were considered statistically significant. The STATA version 12.0 (Stata Corp, College Station, TX) was used to perform all analyses.
Results
Search results and methodological quality of the included studies. There were 35 studies as a result of the search and screening. During the extraction of data, 5 articles were excluded because they did not provide the allele frequencies needed for the OR calculations. Therefore, a total of 30 studies, with 106,312 cases and 140,939 controls, were finally included [6, Figure 1 ). However, no significantly increased risk was found among Africans for all genetic models.
We further performed an analysis to test for differences in the associations of the polymorphism with breast cancer risk with respect to different prognostic factors. We compared estrogen receptor-positive (ER+) case subjects with estrogen receptor-negative (ER-) case subjects and, in a similar fashion, progesterone receptor-positive (PR+) case subjects with receptor-negative (PR-) case subjects. Stratification of tumors by ER status indicated that rs13387042 had a stronger association with ER+ tumors (OR 1.14, 95%CI 1.11-1.17) than ER-tumors (OR 1.05, 95%CI 1.01-1.09) ( Figure 2 ). In addition, rs13387042 was associated with greater risk of PR+ tumors (OR 1.16, 95%CI 1.12-1.19) than PR-tumors (OR 1.07, 95%CI 1.03-1.12) (Figure 3 ). (Figure 7) . Sensitivity analyses. Influence analysis was performed to assess the influence of each individual study on the pooled OR by the sequential removal of individual studies. No individual study significantly affected the pooled ORs, as the results show ( Figure S1, S2) .
Publication bias. Both Begg's funnel plot and Egger's test were conducted to estimate the publication bias of the articles. The shape of the funnel plot for the polymorphisms was symmetric ( Figure S3, S4) , which indicated no evidence of publication bias for rs13387042 and rs3803662.
Discussion
The pathogenesis of the carcinogenesis and progression of BC is still not understood. However, previous evidence suggests that it is a polygenic disease that is also related to environmental factors. Recently, GWAS have discovered that the common variations rs13387042 at 2q35 and rs3803662 at 16q12 were associated with BC risk, as described above. However, limitations, such as small size, ethnic differences, and BC subtype, of the studies made the results inconsistent. Therefore, a meta-analysis was performed to explore the heterogeneity of the polymorphisms and more precisely assess the effect of the polymorphisms on BC risk.
Our analysis showed that the 2q35 rs13387042 G>A and 16q12 rs3803662 C>T polymorphisms were significantly correlated with increased BC risk. The A allele of the 2q35 rs13387042 variant and T allele of the 16q12 rs3803662 C>T variant were low-penetrant risk factors for developing BC. In the analysis stratified by ethnicity, significantly increased risk was found among Caucasians, Asians and mixed ethnicities. However, no significantly increased risk was found among Africans. Some points may be responsible for this result. For the rs13387042 polymorphism, the frequencies of the risk allele differed from 0.510 in Caucasians [6] to 0.060 in the Chinese population [17] . For the rs3803662 polymorphism, the frequency of risk for the T allele varied markedly between ethnicities, from 0.341 in European-Americans to 0.530 in Japanese-Americans [31] . So, ethnic differences might contribute to the inconsistent results. Furthermore, a polymorphism may affect the BC risk by combining with another nearby variance, and the pattern of the interaction could differ for different ethnicities. In addition, the particular lifestyles of the The previous studies on 2q35-rs13387042 and 16q12-rs3803662 suggested that the association risk was confined to ER+ tumors [6] . However, in our results, both 2q35 and 16q12 were associated with ER+ tumors and ER-tumors. The difference is that the association for ER+ breast cancer seems to be stronger than that for ER-breast cancer. Similar risks were observed when the results were stratified by PR status. Because the ER and PR statuses are the major markers of breast cancer subtype, these observations suggested that inherited risk variants of these subtypes might vary. Although this observation has no immediate clinical significance, this result provides clues to the biological mechanisms underpinning tumor heterogeneity, which may ultimately lead to improved prevention and treatment.
For rs3803662, when stratified by the BRCA mutation carrier status, a stronger association was observed with BRCA2 carriers than BRCA1 carriers. This result is consistent those from previous studies. The breast cancer risk for BRCA1 and BRCA2 mutation carriers has been estimated to be between 40% and 80% by age 70 [42] [43] [44] . More studies must be performed to uncover the mechanism behind the rs3803662 polymorphism in the BRCA mutation and BC.
2q35-rs13387042 is located in a 90-kb region of high linkage disequilibrium that contains neither known genes nor non-coding RNAs. Trinucleotides repeat containing 9 (TNRC9) is a gene located at chromosome 16q12, and several polymorphisms, including rs3803662, have been identified in this gene. Although their functions are uncertain, the two polymorphisms are newly described risk factors for breast cancer. Thus, functional studies in this region are likely to lead to a better understanding of the mechanisms of carcinogenesis and progression of breast cancer.
The advantage of the study is its much larger sample size, and it summarises the latest studies on the association between rs13387042, rs3803662 and BC. The qualities of case-control studies meet our inclusion criterion. Furthermore, the lack of publication bias indicates that the entire pooled result should be unbiased. In addition, we also performed analyses to test for differences in the associations of the polymorphism with breast cancer risk with respect to different hormone receptor statuses, and we analysed the correlation between the BRCA mutation at rs3803662 and BC susceptibility, which has never been explored. However, the limitation in this meta-analysis should be attended. First, the studies in our analysis on Caucasians were more numerous than those of other ethnicities, so the statistical power for the other ethnicities is limited. Second, our results were based on unadjusted estimates, and we were unable to adjust them using possible confounders such as age, smoking, menopausal status, alcohol consumption and other lifestyle risk factors.
In summary, our meta-analysis demonstrated that both rs13387042 and rs3803662 were associated with increased risk of BC, particularly in Caucasian and Asian populations. Due to the limitations of studies of African-descent populations, further studies including a wider spectrum of subjects are needed to investigate the role of these variants in these populations.
Supplementary information is available in the online version of the paper. 
